120 related articles for article (PubMed ID: 18223235)
1. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Klopper JP; Berenz A; Hays WR; Sharma V; Pugazhenthi U; Janssen J; Singh M; Bissonnette RP; Haugen BR
Clin Cancer Res; 2008 Jan; 14(2):589-96. PubMed ID: 18223235
[TBL] [Abstract][Full Text] [Related]
2. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Fu J; Ding Y; Huang D; Li H; Chen X
Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
[TBL] [Abstract][Full Text] [Related]
3. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
4. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
5. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
6. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
Kim HT; Kong G; Denardo D; Li Y; Uray I; Pal S; Mohsin S; Hilsenbeck SG; Bissonnette R; Lamph WW; Johnson K; Brown PH
Cancer Res; 2006 Dec; 66(24):12009-18. PubMed ID: 17178900
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
8. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Klopper JP; Sharma V; Berenz A; Hays WR; Loi M; Pugazhenthi U; Said S; Haugen BR
Mol Cancer; 2009 Mar; 8():16. PubMed ID: 19267912
[TBL] [Abstract][Full Text] [Related]
9. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
Agarwal VR; Bischoff ED; Hermann T; Lamph WW
Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
[TBL] [Abstract][Full Text] [Related]
10. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma.
Shi Y; Zou M; Baitei EY; Alzahrani AS; Parhar RS; Al-Makhalafi Z; Al-Mohanna FA
Cancer Gene Ther; 2008 Feb; 15(2):101-7. PubMed ID: 18197164
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
[TBL] [Abstract][Full Text] [Related]
13. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
14. Selective activity of BS-RNase against anaplastic thyroid cancer.
Kotchetkov R; Cinatl J; Krivtchik AA; Vogel JU; Matousek J; Pouckova P; Kornhuber B; Schwabe D; Cinatl J
Anticancer Res; 2001; 21(2A):1035-42. PubMed ID: 11396137
[TBL] [Abstract][Full Text] [Related]
15. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma.
Pushkarev VM; Starenki DV; Saenko VO; Tronko MD; Yamashita S
Exp Oncol; 2011 Mar; 33(1):24-7. PubMed ID: 21423091
[TBL] [Abstract][Full Text] [Related]
16. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
Cras A; Politis B; Balitrand N; Darsin-Bettinger D; Boelle PY; Cassinat B; Toubert ME; Chomienne C
Clin Cancer Res; 2012 Jan; 18(2):442-53. PubMed ID: 22142826
[TBL] [Abstract][Full Text] [Related]
18. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo.
Celano M; Schenone S; Cosco D; Navarra M; Puxeddu E; Racanicchi L; Brullo C; Varano E; Alcaro S; Ferretti E; Botta G; Filetti S; Fresta M; Botta M; Russo D
Endocr Relat Cancer; 2008 Jun; 15(2):499-510. PubMed ID: 18509002
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
